U-turn by medicines watchdog means about 3,000 women with advanced forms of disease could benefit each year Thousands of women with advanced breast cancer in England and Wales are to be offered a “gamechanging” twice-a-day pill on the NHS after a U-turn by the medicines watchdog. Experts hailed the decision as a “landmark moment”. As many as 3,000 women every year could benefit from capivasertib for hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread. Continue reading...